Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rucaparib combination in mCRPC
NCT04179396Phase 1Completed
- Sponsor
- pharma&
- Start
- Dec 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rucaparib in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by pharma&. Primary endpoints: Pharmacokinetics of Rucaparib at 28 days and Incidence of Dose-Limiting Toxicities at 56 days. Started Dec 2019; status: completed.
02
Drugs
rucaparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04179396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04179396.